OraSure Technologies, Inc. (NASDAQ:OSUR) Receives Average Rating of “Hold” from Brokerages

Shares of OraSure Technologies, Inc. (NASDAQ:OSUR) have been given an average recommendation of “Hold” by the seven ratings firms that are presently covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating and four have assigned a hold rating to the company. The average 12 month target price among analysts that have covered the stock in the last year is $10.00.

A number of brokerages have recently weighed in on OSUR. BidaskClub lowered OraSure Technologies from a “hold” rating to a “sell” rating in a research report on Friday, April 5th. Canaccord Genuity lowered OraSure Technologies from a “buy” rating to a “hold” rating and set a $10.00 price objective on the stock. in a research report on Thursday, May 9th. Finally, Zacks Investment Research lowered OraSure Technologies from a “hold” rating to a “sell” rating in a research report on Wednesday, May 15th.

Shares of OSUR stock traded up $0.08 during trading hours on Monday, reaching $8.62. The company’s stock had a trading volume of 11,709 shares, compared to its average volume of 483,618. The company has a market capitalization of $529.91 million, a PE ratio of 17.20, a P/E/G ratio of 3.01 and a beta of 1.23. OraSure Technologies has a one year low of $8.01 and a one year high of $17.97. The business’s fifty day moving average is $8.78. The company has a debt-to-equity ratio of 0.02, a current ratio of 7.52 and a quick ratio of 6.56.

OraSure Technologies (NASDAQ:OSUR) last issued its quarterly earnings data on Wednesday, May 8th. The medical instruments supplier reported ($0.05) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.06) by $0.01. The firm had revenue of $30.12 million for the quarter, compared to analyst estimates of $29.66 million. OraSure Technologies had a return on equity of 7.87% and a net margin of 11.34%. The business’s quarterly revenue was down 28.3% compared to the same quarter last year. During the same period last year, the company earned $0.07 EPS. Analysts expect that OraSure Technologies will post 0.23 earnings per share for the current year.

In other news, CFO Roberto Cuca bought 10,000 shares of the stock in a transaction dated Friday, May 10th. The stock was bought at an average price of $9.03 per share, for a total transaction of $90,300.00. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Stephen S. Phd Tang sold 16,667 shares of the firm’s stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $11.10, for a total value of $185,003.70. Following the completion of the transaction, the chief executive officer now owns 135,627 shares of the company’s stock, valued at approximately $1,505,459.70. The disclosure for this sale can be found here. In the last 90 days, insiders bought 21,000 shares of company stock valued at $184,360. 1.70% of the stock is currently owned by company insiders.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Dimensional Fund Advisors LP lifted its stake in shares of OraSure Technologies by 1.1% in the 4th quarter. Dimensional Fund Advisors LP now owns 2,918,182 shares of the medical instruments supplier’s stock valued at $34,084,000 after purchasing an additional 31,216 shares during the period. American Capital Management Inc. raised its stake in OraSure Technologies by 67.2% during the first quarter. American Capital Management Inc. now owns 2,876,592 shares of the medical instruments supplier’s stock valued at $32,074,000 after buying an additional 1,156,560 shares during the last quarter. Penn Capital Management Co. Inc. raised its stake in OraSure Technologies by 42.0% during the fourth quarter. Penn Capital Management Co. Inc. now owns 1,009,271 shares of the medical instruments supplier’s stock valued at $12,315,000 after buying an additional 298,618 shares during the last quarter. D. E. Shaw & Co. Inc. raised its stake in OraSure Technologies by 11.0% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 858,034 shares of the medical instruments supplier’s stock valued at $10,022,000 after buying an additional 85,188 shares during the last quarter. Finally, Geode Capital Management LLC raised its stake in OraSure Technologies by 10.7% during the fourth quarter. Geode Capital Management LLC now owns 716,260 shares of the medical instruments supplier’s stock valued at $8,364,000 after buying an additional 69,347 shares during the last quarter. Institutional investors own 91.49% of the company’s stock.

OraSure Technologies Company Profile

OraSure Technologies, Inc, together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, OSUR and DNAG. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests.

Read More: What defines an oversold asset?

Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.